Education
About Us
Working with TipRanks
Follow Us
Genfit SA (FR:GNFT)
:GNFT
GNFT Stock Chart & Stats
€7.88
-€0.03(-0.72%)
At close: 4:00 PM EST
€7.88
-€0.03(-0.72%)
Day’s Range― - ―
52-Week Range€2.62 - €8.30
Previous CloseN/A
Volume32.76K
Average Volume (3M)245.75K
Market Cap
€391.96M
Enterprise Value€424.11M
Total Cash (Recent Filing)€107.51M
Total Debt (Recent Filing)€138.91M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Apr 02, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding50,036,790
10 Day Avg. Volume239,968
30 Day Avg. Volume245,745
Financial Highlights & Ratios
PEG Ratio-1.12
Price to Book (P/B)2.57
Price to Sales (P/S)2.65
P/FCF Ratio12.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.40Price Target Upside6.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Return To ProfitabilityGenfit's 2024 return to profitability, coupled with an exceptionally high gross margin, indicates the company can convert revenue to profit when sales stabilize. Durable operational improvements and stronger EBIT/EBITDA margins suggest operating leverage that can support continued R&D funding and program advancement over months.
Strong Cash GenerationElevated free cash flow relative to earnings and strong operating cash conversion show Genfit is generating cash from operations rather than relying solely on financing. This improves the company's ability to fund clinical programs, meet milestone obligations and sustain operations through development timelines over the medium term.
Balanced Capital StructureA moderate debt-to-equity ratio and a near 46% equity ratio indicate a balanced use of leverage and a meaningful equity cushion. This structural balance supports access to debt financing if needed while preserving capacity to absorb clinical or program setbacks without immediate solvency pressure.
Bears Say
Volatile Revenue TrendsHistorically volatile revenues and a large negative multi-year growth figure undermine predictability of top-line performance. For a biotech reliant on milestone/licensing timing and clinical progress, this volatility reduces visibility into sustainable cash inflows and complicates multi-quarter planning and investment decisions.
Declining Total AssetsA meaningful decline in total assets can reflect disposals, impairments or shrinking operational scale, weakening the company's resource base. Over a 2–6 month horizon this reduces collateral for lenders, limits balance-sheet flexibility and may constrain the scope or pace of clinical and commercial programs.
Low Shareholder ReturnsA low ROE signals limited profitability relative to shareholder capital. For investors and potential partners this suggests capital is not being converted efficiently into returns, which can make raising equity or securing favorable partnership terms harder and pressure long-term funding options.
Genfit News
GNFT FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest stock price was €2.62 and its highest was €8.30 in the past 12 months.
What is Genfit SA’s market cap?
Genfit SA’s market cap is €391.96M.
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Apr 02, 2026 which is in 38 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Sep 22, 2025. The company reported -€0.2 earnings per share for the quarter, missing the consensus estimate of €1.025 by -€1.225.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Undervalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is -0.03.
How many shares outstanding does Genfit SA have?
Genfit SA has 50,036,790 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of -€0.2 in its last earnings report, missing expectations of €1.025. Following the earnings report the stock price went down -5.039%.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in FR:GNFT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genfit SA
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
GNFT Stock 12 Month Forecast
Average Price Target
€8.40
▲(6.60% Upside)
Technical Analysis
Innate Pharma SA
―
Abivax SA
―
DBV Technologies
―
Nanobiotix
―
OSE Immunotherapeutics SA
―
Options Prices
Currently, No data available
---